Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
Details : IQVIA Biotech is positioned to collaborate with ASLAN on development plans for ASLAN003 in inflammatory bowel disease, with clinical trials commencing early next year. Enrollment of the first patient in the ASLAN004 Phase 2b trial is expected in the four...
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : Undisclosed
December 06, 2021
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : ASLAN Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
Details : The abstract accepted for poster presentation, titled “A phase 1, open-label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor" will be prese...
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : Not Applicable
May 05, 2021
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
Details : ASLAN004 was found to be well tolerated at 400mg and the DMC has recommended that the multiple ascending dose (MAD) clinical study continue as planned.
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 22, 2020
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The company announced that clinical sites in the US and Australia are now open and ready to enrol patients into its multiple ascending dose (MAD) study testing the first-in-class therapeutic antibody ASLAN004 in moderate to severe atopic dermatitis (AD) ...
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : Not Applicable
September 21, 2020
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study
Details : ASLAN Pharmaceuticals has resumed patient recruitment into its randomised, double-blind, placebo-controlled multiple ascending dose (MAD) study of ASLAN004 in moderate to severe atopic dermatitis.
Brand Name : ASLAN004
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 24, 2020
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Recruitment of new patients into its study of ASLAN004 in moderate to severe atopic dermatitis has been paused in light of recently imposed government restrictions in Singapore.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 13, 2020
Lead Product(s) : ASLAN004
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?